Medtronic (NYSE:MDT) has hired a top regulatory and quality official at Danaher to be its new chief quality officer, CEO Geoff Martha announced on LinkedIn today.
Scott Cundy rose up through the ranks at Danaher over more than a dozen years at the company. He most recently served as its VP of quality, regulatory and clinical affairs for Diagnostics and Life Sciences Platforms.
The hiring is also a homecoming for Cundy. Before Danaher, — in the early 2000s — he held quality, regulatory and clinical roles in Medtronic’s cardiovascular portfolio.
“His robust background in product quality, engineering, and regulatory — along with deep executional experience and operating rigor — will enable us to continue the crucial and impactful work underway in our safety and quality function,” Martha said.
The previous chief quality officer, Noel Colon, has moved into the role of SVP of research and development at Medtronic, according to his LinkedIn page.
Cundy joins Medtronic as the medtech giant seeks to move beyond serious recalls involving its discontinued HVADs, diabetes treatment devices and more.
In addition, an FDA warning letter produced more challenges for the company’s Diabetes business. Martha said in November that the company has addressed 100% of the items in the warning letter.